SYNTHETIC STUDIES ON TUMOR PROMOTERS & INHIBITORS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本项目针对五个具体目标：D.1：合成基于PKC靶向的治疗癌症的有效先导化合物格尼地马林；D.2：开发一种广泛而灵活的抗癌先导化合物瑞香烷家族的先导化合物并研究其活性；D.3：瑞香烷-替格里烷杂化化合物的合成和生物学评价；D.4：劳利马利德类似物的合成和生物学评价，该化合物具有抗紫杉醇耐药癌症的活性；D.5：药物和探针转运体的设计、合成和评估，涉及实时生物发光分析，特别关注转运体结合物，这些转运体结合物是为基于细胞外蛋白酶激活而选择性进入细胞或组织而设计的

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is directed at five specific aims: D.1: The synthesis of gnidimacrin, a potent lead for the treatment of cancer based on PKC targeting; D.2: The development of a general and flexible rout to anticancer leads in the daphnane family and study of their activity; D.3: The synthesis and biological evaluation of daphnane-tigliane hybrids; D.4: The synthesis and biological evaluation of laulimalide analogs, compounds active against taxol resistant cancers; D.5: The design, synthesis, and evaluation of drug and probe transporters involving a real time bioluminescence assay with a specific focus on transporter conjugates that are designed for selective cell or tissue entry based on activation by extracellular proteases